<DOC>
	<DOCNO>NCT00003953</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness doxorubicin docetaxel follow surgery treat woman stage II stage III breast cancer .</brief_summary>
	<brief_title>Chemotherapy Followed Surgery Treating Women With Stage II Stage III Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine clinical pathological response woman stage II-IIIB primary breast cancer preoperative high dose chemotherapy sequential doxorubicin docetaxel . II . Determine safety toxicity regimen patient . III . Determine rate breast conservation surgery patient regimen . IV . Determine clinical response patient docetaxel 3 course doxorubicin . V. Correlate circulate tumor cell shed time surgery clinical response pathological finding patient . VI . Determine whether tumor response correlate HER2/neu expression primary tumor . OUTLINE : Patients receive doxorubicin IV day 1 , 15 , 29 , follow docetaxel IV 1 hour day 43 , 57 , 71 . Filgrastim ( G-CSF ) administer subcutaneously day 3-10 2 week course . Fourteen 21 day follow preoperative chemotherapy , patient undergo radical , modified radical , breast sparing surgery plus axillary lymph node dissection . Patients disease progression inoperable stage IIIB disease remove study . Following surgery , patient stratify one three postoperative regimen : Stratum I : Patients 0 lymph node metastasis receive chemotherapy receive cyclophosphamide , methotrexate , fluorouracil ( CMF ) 4 course . Stratum II : Patients 1-3 lymph node metastasis receive CMF 4 course . Stratum III : Patients least 4 lymph node metastasis stage IIIB may receive high dose chemotherapy stem cell support . Two 6 week surgery , patient undergo breast sparing procedure receive adjuvant radiotherapy . Patients undergo mastectomy receive chest wall supraclavicular radiotherapy initial clinical stage T3 , T4 , N2 . All patient N1 great 4 lymph node N3 receive radiotherapy . Radiotherapy administer 5 day week 5.5 week . Patients positive estrogen progesterone receptor receive oral tamoxifen daily 5 year . Patients follow every 3 month 3 year , every 6 month 5 year , annually thereafter . PROJECTED ACCRUAL : Approximately 27-35 patient accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Eligibility Criteria : Women diagnosis breast cancer establish tissue obtain needle biopsy incisional biopsy . There must residual measurable breast and/or axillary mass biopsy . Clinical stage T1 , N13 , Mo T24 , N03 , Mo . T2N0 lesion &lt; 4cm maximum dimension eligible breast conservation feasible practical without preoperative tumor shrinkage . Patients must willing undergo mastectomy breast sparing procedure plus axillary lymph node dissection . There must evidence systemic metastasis . No prior chemotherapy . Patients may receive 14 day tamoxifen . 3.1.7 Patients &gt; 18years eligible . ECOG performance status 01 . Normal hematologic function define white blood cell count &gt; 3500/111 neutrophil count &gt; 1500411 platelet &gt; 100,000/4 Normal renal function define serum creatinine &lt; 1.5 mg/di . Adequate hepatic function . Bilirubin must &lt; institutional upper limit normal ( ULN ) . Transaminases ( SGOT and/or SGPT ) may 2.5 X institutional ULN alkaline phosphatase &lt; ULN , alkaline phosphatase may 4 X ULN transaminases &lt; ULN . However , patient transaminase elevation &gt; 1.5 X ULN alkaline phosphatase &gt; 2.5 X ULN eligible study ( due decrease clearance docetaxel increase risk toxicity ) . Patients prior CIS cervix nonmelanoma skin cancer eligible . Patients prior DCIS LCIS breast eligible previously treat radiation chemotherapy . Patients prior malignancy include contralateral breast cancer treat curative intent 5 year enrollment eligible . Patients must sign informed consent . Patients prior history malignancy mention section 3.1.12 ineligible . Patients must severe concurrent medical psychiatric illness ( i.e . severe diabetes mellitus , poorly control ischemic heart disease congestive heart failure , severe chronic obstructive restrictive pulmonary disease ) . The interval initial diagnosis breast cancer start treatment must great 8 week . Due anticipate toxicity unborn fetus , excretion chemotherapy breast milk , patient must pregnant lactating must use effective contraception treatment . No history hypersensitivity reaction preparation contain polysorbate 80 , 3.2.6 Patients must peripheral neuropathy grade 2 high . Patients must prior radiation &gt; 25 % bone marrow</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
</DOC>